Two Sigma Investments LP Has $31.02 Million Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Two Sigma Investments LP increased its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 4.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 861,188 shares of the medical device company's stock after purchasing an additional 36,475 shares during the quarter. Two Sigma Investments LP owned approximately 1.31% of Tandem Diabetes Care worth $31,020,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Tandem Diabetes Care by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock worth $267,989,000 after buying an additional 77,451 shares in the last quarter. ArrowMark Colorado Holdings LLC boosted its stake in Tandem Diabetes Care by 14.1% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 2,723,715 shares of the medical device company's stock worth $98,108,000 after purchasing an additional 337,026 shares in the last quarter. GW&K Investment Management LLC grew its holdings in shares of Tandem Diabetes Care by 18.0% during the fourth quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company's stock worth $76,488,000 after purchasing an additional 323,674 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its stake in shares of Tandem Diabetes Care by 189.0% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,661,013 shares of the medical device company's stock valued at $59,830,000 after buying an additional 1,086,337 shares in the last quarter. Finally, Park West Asset Management LLC raised its holdings in shares of Tandem Diabetes Care by 49.5% in the fourth quarter. Park West Asset Management LLC now owns 1,600,000 shares of the medical device company's stock valued at $57,632,000 after buying an additional 530,000 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Piper Sandler dropped their target price on shares of Tandem Diabetes Care from $36.00 to $30.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. Canaccord Genuity Group lifted their price objective on Tandem Diabetes Care from $58.00 to $59.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Barclays decreased their target price on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Citigroup increased their price target on shares of Tandem Diabetes Care from $20.00 to $24.00 and gave the company a "neutral" rating in a research report on Thursday. Finally, Mizuho began coverage on shares of Tandem Diabetes Care in a research note on Thursday, April 10th. They set a "neutral" rating and a $20.00 price objective on the stock. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Tandem Diabetes Care presently has an average rating of "Moderate Buy" and a consensus price target of $37.47.

Tandem Diabetes Care Stock Up 0.4%

Shares of NASDAQ:TNDM traded up $0.08 during midday trading on Monday, reaching $20.72. 945,052 shares of the company were exchanged, compared to its average volume of 1,487,297. The firm has a market cap of $1.38 billion, a PE ratio of -10.74 and a beta of 1.47. Tandem Diabetes Care, Inc. has a fifty-two week low of $15.75 and a fifty-two week high of $53.69. The stock has a fifty day simple moving average of $19.40 and a two-hundred day simple moving average of $27.42. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.07). Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The firm had revenue of $234.42 million for the quarter, compared to analyst estimates of $220.19 million. During the same period in the prior year, the company earned ($0.65) earnings per share. The firm's quarterly revenue was up 22.3% on a year-over-year basis. As a group, sell-side analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.

Insiders Place Their Bets

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos purchased 10,538 shares of the business's stock in a transaction on Friday, March 7th. The shares were purchased at an average cost of $18.12 per share, with a total value of $190,948.56. Following the transaction, the chief operating officer now directly owns 10,538 shares of the company's stock, valued at $190,948.56. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.90% of the company's stock.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.